Complete urological evaluation including sperm DNA fragmentation in male systemic lupus erythematosus patients

Imagem de Miniatura
Arquivos
art_TISEO_Complete_urological_evaluation_including_sperm_DNA_fragmentation_in_2019.PDF (200.98 KB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS LTD
Autores
Citação
LUPUS, v.28, n.1, p.59-65, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective To evaluate sperm DNA fragmentation analysis in non-azoospermic male systemic lupus erythematosus (SLE) patients. Methods Twenty-eight consecutive male SLE patients (American College of Rheumatology criteria) and 34 healthy controls were evaluated for demographic/exposures data, urological evaluation, hormone profile and sperm analysis (including sperm DNA fragmentation). Clinical features, disease activity/damage scores and treatment were also evaluated. Results The median age (33 (20-52) vs. 36.5 (25-54) years, P = 0.329) and frequency of varicocele (25% vs. 32%, P = 0.183) were similar in SLE patients and healthy controls. Sperm DNA fragmentation showed significantly higher levels of cells class III (44 (9-88) vs. 16.5 (0-80)%, P = 0.001) and cell class IV (10.5 (3-86) vs. 7 (0-36)%, P = 0.039) in SLE. The sperm DNA fragmentation index was also significantly higher in SLE patients (62 (31-97) vs. 25.5 (0-100)%, P < 0.001). Conventional sperm parameters (including sperm count, motility and morphology) were similar in both groups. In SLE patients no correlations were observed between sperm DNA fragmentation index and age, disease duration, Systemic Lupus Erythematosus Disease Activity Index 2000 and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index scores, and cumulative dose of prednisone, hydroxychloroquine, intravenous cyclophosphamide, methotrexate, azathioprine and mycophenolate mofetil (P > 0.05). Further analysis of SLE patients treated with and without intravenous cyclophosphamide showed that total sperm motility was significantly lower in the former group (64% (15-83) vs. 72% (57-86), P = 0.024). The sperm DNA fragmentation index was alike in both groups (52.5 (31-95) vs. 67.5 (34-97)%, P = 0.185). Conclusions To our knowledge, this is the first demonstration that male non-azoospermic SLE patients have increased sperm DNA fragmentation without evident gonadal dysfunction. Intravenous cyclophosphamide does not seem to be a major determinant for this abnormality. Future prospective study is necessary to determine the impact of this alteration in these patients' fertility.
Palavras-chave
Systemic lupus erythematosus, sperm DNA fragmentation, testicular, sperm, hormone
URI
https://observatorio.fm.usp.br/handle/OPI/30786
Referências
  1. Bisht Shilpa, 2017, Front Biosci (Schol Ed), V9, P420
  2. Blumer CG, 2012, BJU INT, V109, P259, DOI 10.1111/j.1464-410X.2011.10240.x
  3. Cho CL, 2017, TRANSL ANDROL UROL, V6, pS366, DOI 10.21037/tau.2017.07.28
  4. Donnelly ET, 2000, HUM REPROD, V15, P1552, DOI 10.1093/humrep/15.7.1552
  5. Farhat J, 2016, REV BRAS REUMATOL, V56, P212, DOI 10.1016/j.rbre.2015.08.005
  6. Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303
  7. Gladman DD, 2002, J RHEUMATOL, V29, P288
  8. Guzick DS, 2001, NEW ENGL J MED, V345, P1388, DOI 10.1056/NEJMoa003005
  9. Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
  10. Lu JC, 2018, REPROD BIOL ENDOCRIN, V16, DOI 10.1186/s12958-018-0345-y
  11. Oliveira JBA, 2018, ANDROLOGIA, V50, DOI 10.1111/and.12889
  12. Ostensen M, 2011, RHEUMATOLOGY, V50, P657, DOI 10.1093/rheumatology/keq350
  13. Rabelo CN, 2013, CLIN RHEUMATOL, V32, P109, DOI 10.1007/s10067-012-2083-4
  14. Shamsi MB, 2011, J ASSIST REPROD GEN, V28, P1073, DOI 10.1007/s10815-011-9631-8
  15. Silva CA, 2014, AUTOIMMUN REV, V13, P431, DOI 10.1016/j.autrev.2014.01.024
  16. Silva CAA, 2007, LUPUS, V16, P593, DOI 10.1177/096120330707077538
  17. Silva CAA, 2002, J RHEUMATOL, V29, P2000
  18. Silva CA, 2012, CLIN REV ALLERG IMMU, V42, P256, DOI 10.1007/s12016-011-8281-z
  19. Silva CA, 2010, ARTHRIT CARE RES, V62, P1682, DOI 10.1002/acr.20323
  20. Silva CA, 2016, EXPERT REV CLIN IMMU, V12, P301, DOI 10.1586/1744666X.2016.1123621
  21. Soares PMF, 2007, ARTHRITIS RHEUM-US, V56, P2352, DOI 10.1002/art.22660
  22. Suehiro RM, 2008, RHEUMATOLOGY, V47, P1692, DOI 10.1093/rheumatology/ken338
  23. Tajar A, 2010, J CLIN ENDOCR METAB, V95, P1810, DOI 10.1210/jc.2009-1796
  24. Tiseo BC, 2016, INT BRAZ J UROL, V42, P11, DOI 10.1590/S1677-5538.IBJU.2014.0595
  25. Vecchi AP, 2011, LUPUS, V20, P512, DOI 10.1177/0961203310384121
  26. WHO, 2010, WHO LAB MAN EX PROC

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Carregar mais